
    
      This trial is a prospective, open, single-arm phase II clinical trial. The trial will enroll
      40 patients with nasopharyngeal cancer stage III-IVA (UICC 8th edition). Subjects will
      receive paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab)
      neoadjuvant therapy and radical concurrent chemotherapy and radiotherapy.
    
  